Collegium Pharmaceutical (COLL) Operating Expenses (2014 - 2026)

Collegium Pharmaceutical's Operating Expenses history runs 13 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 14.16% year-over-year to $86.4 million in Q1 2026; TTM through Mar 2026 was $294.3 million, a 22.08% increase from a year earlier, with the FY2025 full-year figure at $283.6 million, up 36.72% from the prior year.
• Operating Expenses climbed to $86.4 million in Q1 2026 per COLL's latest filing, from $67.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $86.4 million in Q1 2026 and bottomed at $32.9 million in Q4 2023.
• The 5-year median for Operating Expenses is $52.8 million (2023), against an average of $53.7 million.
• Biggest YoY gain for Operating Expenses was 82.68% in 2024; the steepest drop was 20.45% in 2024.
• Year by year, Operating Expenses stood at $38.0 million in 2022, then dropped by 13.38% to $32.9 million in 2023, then surged by 82.68% to $60.2 million in 2024, then advanced by 12.37% to $67.6 million in 2025, then grew by 27.7% to $86.4 million in 2026.
• Per Business Quant, the three latest COLL Operating Expenses figures stand at $86.4 million (Q1 2026), $67.6 million (Q4 2025), and $67.1 million (Q3 2025).